Short- and long-term outcomes of gestational diabetes and its treatment on fetal development.
Sarah R Murray, Rebecca M Reynolds
https://pubmed.ncbi.nlm.nih.gov/32946125/Actively Recruiting
Led by Rutgers, The State University of New Jersey · Updated on 2026-07-31
864
Participants Needed
3
Research Sites
43 weeks
Total Duration
Hypertensive disorders during pregnancy HDP and gestational diabetes GDM are common complications that can cause serious health problems for mothers and babies. Researchers are studying the MOM-HD program, a mobile app-based telemonitoring system, to see if it helps women with HDP and GDM manage their blood pressure and blood glucose better. This study is a randomized controlled trial conducted in real-world hospital settings in Nepal, aiming to assess both the effectiveness and how well the program can be implemented in clinical care. The MOM-HD program includes training for patients and their families, provision of blood pressure monitors and glucometers, and a mobile app for uploading daily readings. Participants also have biweekly tele-visits with nurses who review their data and provide counseling. The study compares standard antenatal care alone to standard care plus the MOM-HD program, from enrollment during pregnancy up to 6 weeks after delivery. The program also involves ongoing technical support, financial assistance for home monitoring, and provider feedback to support sustained use. Participants will be followed from 24 to 30 weeks of pregnancy until 6 weeks postpartum. Researchers will monitor clinical outcomes such as blood pressure and blood glucose levels, and adverse perinatal events like neonatal intensive care admissions and cesarean deliveries. The study collects data through the app and provider portal, with regular telehealth check-ins, and evaluates implementation success and costs. Total participation lasts from enrollment in late pregnancy through the postpartum period, allowing comprehensive assessment of both health and program impact.
CONDITIONS
Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD)
S
Shristi Rawal, PhD
A
Archana Shrestha, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rutgers, The State University of New Jersey
Lead Sponsor
Dhulikhel Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From 24-30 weeks gestation to 6 weeks postpartum
Participants receive either the MOM-HD telemonitoring program plus standard care or standard care alone, from enrollment during pregnancy until 6 weeks postpartum. The MOM-HD group uses a mobile app and devices to monitor blood pressure and blood glucose, with biweekly tele-visits from nurses. The standard care group attends frequent hospital visits for monitoring and counseling.
Biweekly tele-visits for MOM-HD group; multiple hospital visits for standard care group
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sarah R Murray, Rebecca M Reynolds
https://pubmed.ncbi.nlm.nih.gov/32946125/Lale Say, Doris Chou, Alison Gemmill...
https://pubmed.ncbi.nlm.nih.gov/25103301/R E Glasgow, T M Vogt, S M Boles
https://pubmed.ncbi.nlm.nih.gov/10474547/Rutgers, The State University of New Jersey
Lead Sponsor
Dhulikhel Hospital
Collaborating Sponsor